Table 5.
Univariate analysis of the clinic characteristics associated to the positivity of mpMRI and 18F-CH PET/CT
| mpMRI | 18F-CH PET/CT | |||
|---|---|---|---|---|
| OR (95% CI) | p value | OR (95% CI) | p value | |
| Age, years | 1.01 (0.93–1.10) | 0.759 | 1.02 (0.93–1.12) | 0.694 |
| Preoperative PSA, ng/mL | 1.05 (0.95–1.15) | 0.344 | 0.98 (0.89–1.07) | 0.630 |
| Pathologic T stage, T3 | 4.24 (0.94–19.26) | 0.061 | 2.86 (0.69–11.82) | 0.146 |
| Pathologic N stage, Nx | 0.93 (0.26–3.41) | 0.917 | 0.50 (0.13–1.86) | 0.301 |
| Pathologic Gleason score, > 7 | 4.62 (0.83–25.73) | 0.081 | 13.91 (1.54–125.63) | 0.019 |
| Positive surgical margin | 0.69 (0.19–2.53) | 0.578 | 0.34 (0.09–1.30) | 0.116 |
| Perineural Invasion | 1.30 (0.36–4.72) | 0.691 | 1.02 (0.28–3.68) | 0.973 |
| PSA levels, ng/mL | ||||
| Post radical prostatectomy | 20.66 (0.45–964.07 | 0.121 | 2.17 (0.71–6.63) | 0.172 |
| On day of biochemical failure | 30.90 (1.50–635.84) | 0.026 | 2.48 (0.76–8.15) | 0.135 |
| On day of MRI-PET/CT | 1.62 (0.88–2.98) | 0.122 | 1.64 (0.90–2.99) | 0.110 |
| Lowest PSA level after surgery | 16.77 (0.530–531.40) | 0.110 | 2.03 (0.72–5.69) | 0.180 |
| Treatment before mpMRI/choline PET/CT | ||||
| Radical prostatectomy and hormonotherapy or radiotherapy | 1.63 (0.38–6.87) | 0.509 | 0.67 (0.16–2.73) | 0.573 |
| Time from prostatectomy | ||||
| To first PSA recurrence | 0.99 (0.95–1.03) | 0.568 | 0.98 (0.94–1.01) | 0.217 |
| To MRI-PET/CT | 1.00 (0.98–1.02) | 0.807 | 0.99 (0.97–1.01) | 0.203 |
| PSA doubling time, months | 1.02 (0.92–1.12) | 0.772 | 0.94 (0.85–1.05) | 0.271 |
Statistically significant value, p < 0.05 are in bold